ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00466063
Collaborator
(none)
108
23
98
4.7
0

Study Details

Study Description

Brief Summary

This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Actual Enrollment :
108 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Study Start Date :
May 1, 2007
Actual Primary Completion Date :
Jul 1, 2015
Actual Study Completion Date :
Jul 1, 2015

Arms and Interventions

Arm Intervention/Treatment
ICL670

ICL670

Drug: Deferasirox

Outcome Measures

Primary Outcome Measures

  1. Safety - renal and hepatic function monitoring. [5 years]

Secondary Outcome Measures

  1. Adverse events [5 years]

  2. Longitudinal ferritin levels [5 years]

  3. Assessment of auditory and ophthalmologic status [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 5 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • History of transfusion-dependent anemia.

  • History of iron overload

Exclusion Criteria:
  • Patients with non-transfusional hemosiderosis.

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of South Alabama Medical Center Mobile Alabama United States 36604
2 Children's Hospital Los Angeles Los Angeles California United States 90027
3 Children's Hospital Oakland Oakland California United States 94609
4 Children's Hospital of Orange County Orange California United States 92868-3874
5 Stanford University Medical Center Stanford California United States 94304
6 MD Anderson Cancer Center - Orlando Orlando Florida United States 32806
7 St. Joseph's Children's Hospital of Tampa Tampa Florida United States 33609
8 Children's Memorial Hospital Chicago Illinois United States 60614-3394
9 Children's Hospital Boston Boston Massachusetts United States 02115
10 Hackensack University Medical Center Hackensack New Jersey United States 07601
11 St. Joseph's Children's Hospital Paterson New Jersey United States 07503
12 The Brooklyn Hospital Center Brooklyn New York United States 11201
13 Schneider Children's Hospital New York New York United States 11040
14 SUNY - Upstate Medical University Syracuse New York United States 13210
15 East Carolina University Greenville North Carolina United States 27858
16 Akron Children's Hospital Akron Ohio United States 44308-1062
17 Children's Medical Center Dayton Ohio United States 45404
18 Oklahoma State University Health Sciences Center Oklahoma City Oklahoma United States 73104
19 Penn State University / Milton S. Hershey Medical Center Hershey Pennsylvania United States 17033-0850
20 St. Jude Children's Research Hospital Memphis Memphis Tennessee United States 38105-2794
21 Cook's Children's Medical Center Fort Worth Texas United States 76104
22 Texas Children's Hospital Houston Texas United States 77030
23 Children's Hospital of the King's Daughters Norfolk Virginia United States 23507

Sponsors and Collaborators

  • Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00466063
Other Study ID Numbers:
  • CICL670A2411
First Posted:
Apr 27, 2007
Last Update Posted:
Dec 29, 2015
Last Verified:
Dec 1, 2015
Keywords provided by Novartis Pharmaceuticals
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 29, 2015